New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

KGK Synergize Inc. settles lawsuit with SourceOne Global Partners

KGK Synergize Inc. settles lawsuit with SourceOne Global Partners
Details of the settlement are confidential and will remain undisclosed.

KGK Synergize Inc. (“KGK”), a product development and contract research organization for the health nutrition industry, announced today the settlement of the lawsuit against SourceOne Global Partners, Inc., initiated by SourceOne on December 29, 2008, in U.S. District Court for the Northern District of Illinois.  Details of the settlement are confidential and will remain undisclosed.

“KGK is pleased to have resolved this matter on business terms in lieu of further protracted litigation,” said Najla Guthrie, CEO of KGK.  KGK’s patents remain valid and enforceable.

According to Ms. Guthrie, Sytrinol® is available through its distribution licensee, Proprietary Nutritionals, Inc. (“PNI”), a subsidiary of Pharmachem Laboratories, Inc.  “We look forward to continued growth in sales of Sytrinol® through our partner, PNI, and working with current and future distributors to offer this innovative cholesterol ingredient to consumers globally.”

Sytrinol® is a patented and proprietary formula derived from natural citrus and palm fruit extracts. It combines polymethoxylated flavones (PMFs), delta, gamma, and alpha tocotrienols and other proprietary ingredient components which has been shown in multiple clinical trials to support healthy cholesterol levels. Additionally, Sytrinol® is a powerful antioxidant with numerous heart health benefits.

KGK also continues to offer its branded ingredients, Diabetinol™ and Dermytol™, both of which are backed by clinical trials.

About KGK Synergize Inc:

KGK conducts human clinical trials for the health nutrition industry and specializes in developing clinical studies that meet FDA/FTC and Health Canada regulations. KGK also offers clinical trial services to assist companies in substantiating claims and provides comprehensive final reports to be submitted to regulatory agencies as is. In addition to its contract research capabilities, KGK has a Product Development Division which brings new and innovative natural health products to the point where they are ready to be manufactured and marketed. These products include Sytrinol® for cardiovascular health, Diabetinol™ for the treatment and/or prevention of Type II Diabetes, and Dermytol™, a new product for the protection of sun damage to the skin.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.